Canada: PMPRB Releases Discussion Guide for Consultations on its Excessive Price Guidelines

In late May, the Patented Medicine Prices Review Board (the "Board") released a Discussion Guide (the "Discussion Guide") for consultations on the Board's Excessive Price Guidelines (the "Guidelines"). The purpose of the Discussion Guide is to obtain feedback on specific issues arising from the Guidelines, including ideas on possible options for change. Written feedback is due no later than AUGUST 25, 2006. It is expected that the Board will conduct face to face consultations in November, 2006.

The Board is seeking input into three specific issues arising from the Guidelines, as follows:

  • The appropriateness of the current approach to the categorization of new patented medicines;
  • The appropriateness of the current approach used to review the introductory prices of new patented medicines; and
  • Whether the Guidelines should address the direction in the Patent Act to consider "any market".

The Discussion Guide indicates that at this time, the Board has no set position on whether or not the Guidelines should be changed.

ISSUE NO. 1: The Appropriateness of the Current Approach to the Categorization of New Patented Medicines

Under the Guidelines, there are three categories for new patented drug products. Category 1 products are a new strength or dosage form of an existing medicine. Category 3 products are those that provide moderate, little or no therapeutic advantage over comparable medicines ("me too" drugs). Category 2 products are ones that provide a breakthrough or substantial improvement over existing medicines.

Under definitions in the Guidelines, a "breakthrough" is the first drug product to be sold in Canada that effectively treats a particular illness or effectively addresses a particular indication. A "substantial improvement" is a drug product that, relative to other drug products in Canada, provides substantial improvement in therapeutic effects (such as increased efficacy or major reductions in dangerous adverse reactions) or provides significant savings to the Canadian health care system.

The Discussion Guide asks three questions in relation to this issue:

  1. Are the new patented drug categories and their definitions appropriate?
  2. Is it important to distinguish a medicine that offers "moderate therapeutic improvement" from a medicine that provides "little or no therapeutic improvement"? If yes, why is it important? If not, why not?
  3. If the answer to question 2 above is yes, on what basis would a new medicine that offers "moderate therapeutic improvement" be distinguished from a new medicine that provides "little or no therapeutic improvement"?

Issue No. 2: Is the Current Approach Used to Review the Introductory Prices of New Patented Medicines Appropriate

The Discussion Guide reviews the tests the Board Staff applies to determine whether the price of a patented drug product falls within the Guidelines and is not excessive.

The Reasonable Relationship Test is used for most Category 1 drug products. The introductory price of a Category 1 drug is considered excessive if it does not bear a reasonable relationship to the average Canadian price of the other strengths of the medicine. Where the dosage regimen is different, the Therapeutic Class Comparison Test is used.

The Therapeutic Class Comparison Test is used for Category 3 drug products and some Category 1 drug products (non comparable dosage forms). The price of a new medicine is excessive if it exceeds the highest price of the therapeutically comparable drugs in Canada. When it is impossible or inappropriate to identify therapeutically comparable drugs in Canada, the Median of the International Prices Test is used.

The Median of the International Prices Test is used for Category 2 drug products and some Category 3 drug products. Under this test, the introductory price of a medicine is excessive if it exceeds the median price of the same medicine sold in the comparator countries of France, Germany, Italy, Sweden, Switzerland, the U.K. and the U.S.

Finally, the Highest International Price Comparison Test provides that in addition to the other tests, the Canadian price of a patented medicine can never be the highest relative to the prices of the same medicine in the seven comparator countries.

The Discussion Guide lists four questions in relation to these tests, as follows:

  1. Are the price tests currently used to review the prices of new medicines in the various categories appropriate for that category? Why? Why not? If not, how could these tests be amended to improve their appropriateness?
  2. If you think that medicines that offer "moderate therapeutic improvement" should be distinguished from medicines that provide "little or no therapeutic improvement" what would the appropriate new price test be?
  3. For price review purposes, "comparable medicines" are medicines that are clinically equivalent. Do you have any suggestions as to principles or criteria that should be used in determining how to identify "comparable medicines" for the purpose of inclusion in the above price tests?
  4. Under the current Guidelines, Board Staff compares the Canadian average transaction price of the new medicine to the prices of the same medicine sold in the seven countries listed in the Regulations. However, Section 85(1) of the Patent Act states that the Board should take into consideration "the prices of other comparable medicines in other countries". Should the Guidelines address this factor? If so, how could this factor be incorporated into the price tests for new medicines?

Issue No. 3: Should the Board's Guidelines Address the Direction in the Patent Act to Consider "any market"?

Section 83 of the Patent Act provides that the Board can make a finding of excessive price, and order a price reduction, in respect of the price at which a patented medicine is being sold in "any market" in Canada. However, in conducting its various price tests, the Board currently uses the average transaction price (ATP) for Canada as a whole. As a result, it is possible for different customer classes (wholesalers, hospitals, etc.) and/or different provinces/territories to pay a higher or lower price than others. The variation in the prices charged is usually modest (plus or minus 5%) but it can be as much as 25% above or below the maximum non-excessive price.

The Board asks two questions in relation to this issue, as follows:

  1. Given the price variations by provinces/territories and classes of customer, is it appropriate for the Board to only consider an ATP calculated based on the total revenues from the sales for all provinces/territories and all classes of customer? Why? Why not?
  2. If the current ATP calculation is not appropriate, should the Board review the prices to the different classes of customers and/or the different provinces and territories for all DINs? Or should this level of review be done on a case by case basis, where there is a significant variation in the prices charged?

The full text of the Discussion Guide can be accessed at: .

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.